INTRODUCTION

Top Abstract Introduction Materials and Methods Results Discussion References

The Pasteurella multocida toxin (PMT) is an extremely potent mitogen for Swiss 3T3 cells, other fibroblast cell lines, and early-passage cultures (15, 39). The toxin is produced by some strains of P. multocida and is responsible for the loss of nasal turbinate bone associated with porcine atrophic rhinitis (33). Furthermore, experimental nasal infection with toxigenic P. multocida leads to proliferation of bladder epithelium (17).

PMT interacts with host cell signaling pathways and results in production of inositol triphosphates and diacyl glycerol, with mobilization of Ca²⁺ from intracellular stores and subsequent activation of protein kinase C (48, 49). PMT activates PLC via a G_q-mediated pathway (31, 56, 57), and this heterotrimeric G protein may be the direct target of PMT. The toxin stimulates Ras-dependent ERK activation via transactivation of the epidermal growth factor receptor (44). PMT also induces cytoskeletal rearrangments, with the formation of actin stress fibers and focal adhesions, and causes tyrosine phosphorylation of paxillin and focal adhesion kinase (24). This occurs via activation of the Rho protein and its effector p160/ROCK (51).

There is considerable evidence that PMT is an intracellularly acting toxin. There is a pronounced lag between the addition of toxin to cells and any cellular effects (39). Its action is also inhibited by neutralizing antibody or methylamine added early but not late after toxin. PMT undergoes a conformational change at low pH, which affects its protease sensitivity and circular dichroism spectra (46, 47). This suggests that PMT may be trafficked and perhaps processed through a low-pH compartment. By analogy with other large intracellularly acting toxins, it is predicted to comprise domains for receptor binding, membrane translocation, and catalytic activity.

PMT is a monomeric 146-kDa protein. It has been purified, cloned, and sequenced (3, 26, 27, 34). PMT shares significant homology with the cytotoxic necrotizing factors (CNFs) of Escherichia coli (9, 32). The homology is highest toward the N termini of both toxins. In CNF, the N terminus is known to contain the domains for binding and internalization of the toxin (28). The C terminus of CNF is homologous to the C terminus of the Bordetella dermonecrotic toxin (DNT) (36, 52), and in both toxins this region possesses catalytic activity (22, 28). CNF and DNT have similar enzymatic activities: each modifies small GTP binding proteins of the Rho family by deamidation or transglutamination, respectively, of a specific glutamine residue (11, 16, 29, 30, 42, 43), whereas PMT has a different mode of action. The sequence homologies strongly suggest that PMT has a molecular organization similar to those of CNF and DNT.

In support of this hypothesis, our group previously reported the construction of a mutant near the C terminus of PMT (C1165S) that was completely inactive in cell assays and that had lost all toxicity in vivo (53). This mutation did not grossly affect the structure of the molecule since it had circular dichroism spectra and protease sensitivity patterns similar to those of the wild-type toxin and therefore is probably near the active site. In contrast, it has been reported that the N terminus of PMT possesses catalytic activity, since microinjection of an N-terminal peptide led to a response in voltage-clamped Xenopus oocytes (55). The reasons for this discrepancy remain unclear.

The aim of the present study was to clarify the location of the functional domains of PMT. We demonstrate definitively that PMT has a molecular organization similar to that of CNF and DNT, with the cell-binding and/or internalization domain at the N terminus and the domain for mitogenic activity at the C terminus.

	MATERIALS AND METHODS

Top Abstract Introduction Materials and Methods Results Discussion References

Materials. All chemical reagents were from Sigma, Ltd., unless otherwise stated. Restriction enzymes and DNA-modifying enzymes were purchased from Promega Corporation or New England Biolabs and used according to the manufacturer's instructions. Oligonucleotides were synthesized by Sigma Genosys. Chromatography reagents and [³H]thymidine (code no. TRK296) were purchased from Amersham Pharmacia Biotech.

Bacterial strains, plasmid vectors, and growth conditions. E. coli JM109 was used as a general purpose host for cloning and expression of toxin fragments cloned as glutathione S-transferase (GST) fusions. E. coli XL1-Blue was the host for pTox2 (which expresses full-length recombinant PMT from its own promoter [53]) and for the corresponding mutant toxin plasmid, pC1165S. Novablue (DE3) was the host for expression of the His-tagged PMT fragment. Plasmid vectors pGEX-4T-1 and pGEX-4T-3 were from Amersham Pharmacia Biotech, pET30a was from Novagen, and pGEM-T was from Promega Corporation.

DNA isolation and sequence analysis. Plasmid DNA for use in subcloning was isolated by using Wizard kits (Promega). For sequence analysis, DNA was further purified by using Qiaquick columns (Qiagen). DNA sequencing was performed with a Beckman CEQ2000 automated DNA sequencer.

Site-directed mutagenesis. Mutagenesis was performed by using the Quikchange mutagenesis kit (Stratagene), according to the manufacturer's instructions. For reversal of the C1165S mutation, the following oligonucleotides were used: 5'-GGAAGCTGGCTCTTGTGATTCAGTAAG and 5'-CTTACTGAATCACAAGAGCCAGCTTCC.

Construction of expression plasmids. Plasmids for expression of GST- and His-tagged fusions of PMT and its fragments were constructed as follows.

(i) pGST/681-C. A fragment encoding PMT residues 681 to 1285 was amplified by PCR from pTox2 by using oligonucleotides 8012 (5'-TACATAACAGTAATATC) and PMTSacAS (5'-AGCGAGCTCGCGCTAATAAGATCGATTGC), gel purified by using Geneclean (Anachem), and A-tailed by using Taq polymerase. This fragment was ligated into pGEM-T (Promega) to produce pGEM/681-C. The insert from this was excised by digestion with BstZI, followed by gel purification, and ligated to pGEX-4T-3 digested with NotI.

(ii) pGST/849-C. A fragment encoding residues 849 to 1285 was PCR amplified from pTox2 by using primers 8013 (5'-TTGCCACACGTAACTTT) and PMTSacAS, gel purified, and A-tailed, before ligation into pGEM-T. The 1.6-kb insert was excised from this plasmid by digestion with BstZI and then ligated to pGEX-4T-3 digested with NotI.

(iii) pGST/PMT. The complete PMT gene was PCR amplified from pTox2 by using primers PMTGST (5'-CGCGGATCCATGAAAACAAAACATTTTTTTAACTC) and PMTSacAS, gel purified, A-tailed, and ligated to pGEM-T. The insert was excised from this plasmid by digestion with BamHI and SalI and ligated to pGEX-4T-1 digested with the same enzymes.

(iv) pGST/1-506. This was prepared from pGST/PMT by deletion of residues 507 to 1285 by digestion with XhoI and self-ligation.

(v) p1-506/His. This contains the PMT N terminus with a hexahistidine (His) tag at its C terminus. The N terminus of PMT, including ca. 180 nucleotides upstream, was excised from pTox2 by digestion with XhoI and BamHI and gel purified. This was ligated to pET30a which had been digested with the same enzymes and transformed into E. coli JM109. Plasmid DNA containing the insert was digested with XhoI and treated with mung bean nuclease before self-ligation. This placed the His tag in the same reading frame as the PMT fragment.

Expression and purification of fusion proteins. GST fusion expression plasmids were transformed into E. coli JM109. The bacteria were inoculated into 15 ml of L broth containing ampicillin and cultured overnight at 30°C. They were subcultured into 300 ml of L broth containing ampicillin and grown for 90 to 120 min at 30°C, before the addition of IPTG (isopropyl--D-thiogalactopyranoside) to 0.2 mM, and culture continued for 5 to 6 h. Cells were harvested by centrifugation at 4,000 × g in a Heraeus Biofuge Primo centrifuge, pellets were resuspended in 15 ml of phosphate-buffered saline (PBS), and the cells were lysed by sonication for three rounds of 20-s pulses at a duty cycle of 50% on a Vibra-Cell sonicator (Sonics and Materials, Inc.). Cell debris was removed by centrifugation at 7,000 × g for 10 min. GST fusion proteins were purified from the supernatants by using glutathione-Sepharose beads (Amersham Pharmacia Biotech) according to the manufacturer's instructions. For some applications, the GST tag was cleaved by using a thrombin cleavage capture kit (Novagen) according to the manufacturer's instructions.

Deletion mutagenesis. Random deletion mutants of GST/681-C were prepared by using the Erase-a-Base kit (Promega Corporation) according to the manufacturer's instructions. pGST/681-C was first digested with SalI, protected with phosphorothioate, and then digested with XhoI before deletions were generated with ExoIII. Deletants were cultured to logarithmic phase in 10-ml volumes of L broth, and expression was induced with 0.2 mM IPTG for 2 h, followed by preparation of crude lysates. Expression of polypeptides of the required molecular weight was detected by SDS-PAGE, followed by immunoblotting using PMT polyclonal antisera.

Expression and purification of rPMT and C1165S. The untagged recombinant PMT (rPMT) and its mutant were purified as previously described (53). Glycerol was added to 50% (vol/vol), and preparations were stored at 20°C for up to 1 year.

PAGE. Proteins were separated in denatured form on 4% stacking and 8% resolving gels (25). Proteins were visualized by a silver-staining technique as described previously (14).

Cell culture. Swiss 3T3 cells were cultured in Dulbecco modified Eagle medium (DMEM; Sigma) supplemented with 10% fetal calf serum and containing penicillin G (100 U/ml) and streptomycin (100 µg/ml) at 37°C in 10% CO₂. Cells were passaged before reaching confluency.

DNA synthesis assay. DNA synthesis was measured by determining the incorporation of [³H]thymidine into quiescent Swiss 3T3 cells as described previously (6). Briefly, cells were plated at 2.5 × 10⁴/ml in 24-well plates and incubated for 7 to 8 days until quiescent. Cells were then washed twice in PBS and incubated at 37°C in a 10% CO₂ atmosphere in 1 ml of DMEM-Waymouth medium, 1:1 (vol/vol), containing 0.037 MBq of [³H]thymidine per ml and various concentrations of PMT in triplicate. After 40 h, DNA synthesis was assessed by measuring the level of [³H]thymidine incorporated into the acid-precipitable material.

Competition assay for cell binding. The cell binding of PMT fragments was assessed by determining their ability to compete with PMT in DNA synthesis assays. Swiss 3T3 cells plated at 2.5 × 10⁴ per well in 24-well plates were incubated for 7 days. Cells were washed twice with serum-free DMEM, and then 1 ml of serum-free DMEM was added to each well. Blocking peptides were added at a range of concentrations, and cells were incubated at 37°C for 30 min. PMT was added to 5 ng/ml, and cells incubated for a further 3 h. Wells were washed twice with DMEM, and 1 ml of serum-free 1:1 (vol/vol) DMEM-Waymouth medium containing [³H]thymidine was added. The DNA synthesis assay was continued as described above.

Schild plot analysis: estimation of toxin binding affinity. The ability of the inactive mutant, C1165S, to compete with PMT was used to estimate its apparent binding affinity for cell surface receptors with the Schild plot method (41). The assay was performed essentially as for the competition assay described above, except that a range of concentrations of wild-type toxin and C1165S mutant were added together to washed, quiescent cells in the presence of [³H]thymidine, and incubation was continued for 40 h.

Microinjection. The cytoplasm of quiescent Swiss 3T3 cells plated on coverslips was injected by using an Olympus IMT-2 inverted microscope fitted with Narishige MO-202 micromanipulators. Proteins for injection were prepared in KCl microinjection buffer (10 mM Tris-HCl [pH 7.4], 140 mM KCl, 8 mM NaCl, 1 mM MgCl₂) at 1 to 2 mg/ml. Nonspecific rabbit immunoglobulin G (IgG; 1 mg/ml) was coinjected to allow detection of injected cells. Each dish of cells was subjected to microinjection for a maximum of 15 min, and then the medium was changed to serum-free 1:1 (vol/vol) DMEM-Waymouth medium containing 1:100 bromodeoxyuridine (BrdU) labeling reagent (5-bromo-2'-deoxyuridine labeling and detection kit 1 [Boehringer]). Injected cells were incubated at 37°C for 40 h. Cells were then washed twice in PBS, fixed for 7 min in 3.7% (wt/vol) paraformaldehyde in PBS, and then placed in cold 1:1 (vol/vol) acetone-methanol for 4 min at 4°C. The detection of BrdU was achieved by incubation in PBS containing 1:10 anti-BrdU monoclonal antibody (Boehringer) according to the manufacturer's instructions for 1 h at 37°C, followed by 1:10 anti-mouse-FITC. Injected cells were detected by using anti-rabbit-IgG-Cy3 (or anti-rabbit-IgG-FITC for morphology experiments) (Sigma), added with the anti-mouse antibody at 1:100. After being washed with PBS, coverslips were mounted in Vectashield anti-fading reagent (Vector Laboratories) and then examined with an Olympus BH2 fluorescence microscope. For antibody injection experiments, injected cells were treated in the same way except that they were subsequently placed in medium containing 1 or 5 ng of PMT/ml.

Polyclonal antisera. Antisera against PMT fragments were raised in sheep. Purified proteins (150 to 200 µg) mixed with Freund incomplete adjuvant in 1-ml volumes were administered at 28-day intervals by subcutaneous injection. The proteins used were GST fusion proteins from which the GST tag had been removed by thrombin cleavage and 1-506/His. Test bleeds of ca. 100 ml were removed after the second, third, and fourth injections and stored at 70°C. A rabbit polyclonal antibody against the formalinized whole toxin was also prepared. The antisera were purified on 1-ml protein G columns equilibrated with 20 mM sodium phosphate (pH 7.0; Amersham Pharmacia Biotech) according to the manufacturer's instructions. Antibody was eluted in 0.1 M glycine (pH 2.7) and neutralized with a few drops of 1 M Tris (pH 9.0). IgG-containing fractions were pooled and dialyzed against PBS at 4°C overnight. The protein concentration was adjusted to 2 mg/ml, and aliquots were stored at 20°C.

Immunoblot analysis. Proteins separated by SDS-PAGE were transferred to Hybond ECL membranes for 1 h at 100 V. Membranes were blocked in TBS-0.5% milk powder for 30 min and then placed in Tween (0.2% [vol/vol])-Tris-buffered saline (20 mM Tris, 500 mM NaCl [pH 7.5]) (TTBS) containing primary antibody at the required dilution. After three washes in TTBS, membranes were incubated in alkaline phosphatase-conjugated secondary antibody in TTBS, followed by three more washes. Blots were developed by using an AP conjugate substrate kit (Bio-Rad).

Immunoprecipitation of PMT. Purified PMT (1 µg) was incubated with 20 µl of a 2-mg/ml concentration of polyclonal antisera for 20 min on ice. Immune complexes were precipitated by the addition of 15 µl of protein G-Sepharose beads (30 min at 4°C). The supernatant was retained for analysis, and the beads were eluted with Laemmli buffer containing 8 M urea. Samples were analyzed for PMT by immunoblot with anti-PMT polyclonal antibody.

Neutralization of PMT by antisera. Swiss 3T3 cells were plated at 2.5 × 10⁴ cells per well in 24-well plates and incubated for 7 days until confluent and quiescent. PMT (1 ng/ml) was preincubated with a range of concentrations of antisera in 1 ml of serum-free 1:1 (vol/vol) DMEM-Waymouth medium containing [³H]thymidine as described above (1 h at room temperature), and this was placed onto the cells after they were washed twice in PBS. After 40 h of incubation, DNA synthesis was assayed as described above.

Proteolysis of PMT. Purified PMT (ca. 300 µg) was incubated with 0.5 µg of endoproteinase Asp-N (Sigma) for 2 h at 37°C. Fragments were separated by SDS-PAGE on a 6% gel and transferred to a Sequi-Blot polyvinylidene difluoride membrane (Bio-Rad). The membrane was stained in Coomassie blue for 1 min and then destained in several changes of 50% (vol/vol) methanol for a few minutes, rinsed in water, and air dried. Protein bands of interest were excised and subjected to N-terminal amino acid sequencing by using an Applied Biosystems sequencer (model 473A).

Sequence analysis. The amino acid sequence of PMT (27) corresponds to that of the sequence database entry with accession number S12998 (TOXA_PASMU). This sequence was analyzed, along with that of a related sequence, CNF1 (9). MALIGN (20) was used to align the two sequences. The secondary structure prediction method of profile-fed neural network systems (PHD; Heidelberg) (37, 38) was used. The presence of domains was predicted by using both the alignment with CNF and the PHD results. A search for the presence of local similarity between regions of PMT and a database of protein sequences available in the Protein Data Bank was performed by using the sequence search tool at the GenQuest(Q) server at the John Hopkins University Bioinformatics Web Server. Sequences that aligned were analyzed by the Smith-Waterman method. Further predictions of structure were made by using the programs THREADER and THREADER 2 (21; http://globin.bio.warwick.ac.uk/~threader).

	RESULTS

Top Abstract Introduction Materials and Methods Results Discussion References

Expression of PMT fragments and production of polyclonal antisera. To identify the regions of PMT responsible for different biological functions, several PMT fragments were cloned with affinity tags to aid their subsequent purification (Fig. 1). The C-terminal fusion proteins, GST/681-C and GST/849-C were found in the insoluble fraction when induction was carried out at 37°C (data not shown), but growth at 30°C led to expression of soluble proteins, so this temperature was routinely used for expression of all fusion proteins. The four proteins were expressed well and were readily purified by standard methods. Figure 1B shows a typical gel of purified fusion proteins. The four fusion proteins were inactive in standard assays for PMT activity, that is, the ability to induce actin stress fibers or induce thymidine incorporation when placed on quiescent Swiss 3T3 cells (not shown).

View larger version (29K): [in this window] [in a new window]   FIG. 1.   (A) Composition of the recombinant polypeptides used in this study relative to full-length PMT (residues 1 to 1285). Open bar, regions derived from the PMT gene; solid bar, location of the GST tag; gray bar, location of the His tag. (B) Purification of recombinant proteins. Purified fusion proteins were separated by SDS-8% PAGE and detected by silver staining. Lanes: 1, GST/1-506; 2, GST/849-C; 3, GST/681-C; 4, 1-506/His. (C) Immunoblot showing the binding of anti-PMT and anti-peptide polyclonal antibodies to recombinant peptides. The antibody is indicated below each blot. For each blot, the lanes contained the following proteins: lane 1, PMT; lane 2, GST/1-506; lane 3, GST/681-C.

Localization of the catalytic domain. To locate the catalytic domain of PMT, purified GST fusion proteins were microinjected into the cytoplasm of quiescent Swiss 3T3 cells. Biological activity was assessed in two ways: the ability to induce cell morphology typical of PMT treated cells and the ability to induce DNA synthesis, which was detected by BrdU incorporation.

View larger version (0K): [in this window] [in a new window]   FIG. 2.   Effects of PMT and of microinjected PMT fragments on the morphology of quiescent Swiss 3T3 cells. (A and B) Representative phase contrast micrographs of Swiss 3T3 cells incubated in serum-free DMEM-Waymouth (1:1 [vol/vol]) for 24 h without (A) or with (B) 5 ng of PMT/ml. (C to E) Representative fluorescence micrographs of cells microinjected with buffer (C), GST/1-506 (D), and GST/681-C (E) as described in Materials and Methods and stained for rabbit IgG to detect injected cells.

View larger version (0K): [in this window] [in a new window]   FIG. 3.   Effects of PMT fragments microinjected into quiescent Swiss 3T3 cells on induction of DNA synthesis. Representative fluorescence micrographs are shown. (A, C, E, and G) Injected cells, detected by use of anti-rabbit IgG-Cy3. (B, D, F, and H) The same fields of cells stained for BrdU. The cells were injected with KCl microinjection buffer (A and B), GST/1-506 (C and D), or GST/681-C (E to H). Panels G and H are at a twofold-higher magnification than panels A to F. The arrows indicate microinjected cells that were BrdU positive.

View larger version (19K): [in this window] [in a new window]   FIG. 4.   (A) Graph showing the percentage of cells microinjected with GST fusion proteins that were BrdU positive. The results show the totals from three separate experiments. At least 40 cells were injected with each protein. Results for the fragments were compared to results for buffer alone by using the chi-square test (, P < 0.001). (B) Inhibition of DNA synthesis induced by PMT in Swiss 3T3 cells microinjected with different antisera. Cells were incubated in the presence of 5 or 1 ng of PMT/ml as shown. The x axis shows the four antisera used. Results for the PMT antibodies were compared to those with preimmune serum by using the chi-square test (, P < 0.01; , P < 0.001).

Mutant C1165S binds specifically to Swiss 3T3 cells. Previous work from this laboratory showed that mutation of cysteine 1165 to serine led to a complete loss of activity without grossly affecting the structure of the toxin molecule (53). The essential role of this residue was verified by reversal of the mutation to cysteine by site-directed mutagenesis. This led to restoration of activity to wild-type levels in the thymidine incorporation assay (data not shown).

View larger version (25K): [in this window] [in a new window]   FIG. 5.   Schild plot analysis for the determination of the affinity of PMT for its cell surface receptor. (A) Competition curves showing the inhibition of PMT activity by the addition of several fixed concentrations of C1165S. The results are expressed as the percentage of tritiated thymidine incorporation induced by 10% fetal calf serum. The buffer control curve was obtained by using the same volume of toxin storage buffer (0.2 M NaCl; 25 mM Tris, pH 6.5; 50% [vol/vol] glycerol) as was present for the highest concentration of C1165S (10 nM). (B) Data were plotted according to the method of Schild (41). T, concentration of PMT to obtain 45% of the thymidine incorporation induced by 10% fetal calf serum; T1, concentration of PMT after addition of a given amount of C1165S which gave the same activity. The dissociation constant, Kd, for the toxin was calculated from the point at which the line intersects the x axis to be ca. 1.5 nM.

Localization of the receptor-binding domain. To localize the receptor-binding domain of PMT to the N or C terminus of the molecule, the ability of the recombinant polypeptides to bind to cells was determined by using the competition assay (Fig. 6A to D). The C-terminal fragments GST/681-C and GST/849-C showed variable results in this assay. This was found to be dependent on the storage buffer. When dialyzed into KCl microinjection buffer (see Materials and Methods), the C-terminal fragments were unable to block PMT activity even at concentrations 10,000 times that of PMT (Fig. 6A). However, in PBS, both proteins inhibited toxin activity (Fig. 6B). This inhibition is probably artifactual since we have observed that these C-terminal fragments form insoluble aggregates under certain conditions, for example, during expression at 37°C. Furthermore, large aggregates of GST/681-C have been observed bound to cells by indirect immunofluoresence by using anti-GST antibody for detection (not shown). Buffer controls showed that neither KCl nor PBS had a significant inhibitory effect on PMT activity in this assay, even when added to 20% of the total volume of medium in the well (the volume of peptides never exceeded 10% of the total volume) (Fig. 6C).

View larger version (36K): [in this window] [in a new window]   FIG. 6.   (A to D) Inhibition of the mitogenic effect of PMT by recombinant proteins. The results are expressed as the percentage of tritiated thymidine incorporation induced by 10% fetal calf serum. Error bars represent the standard deviations obtained from at least three determinations at each point. The x axis values (A, B, and D) represent the ratio of protein concentration in the blocking peptide sample relative to the toxin concentration (i.e., 5 ng/ml). (A) Competition results for PMT fragments prepared in KCl microinjection buffer. (B) Competition results for blocking peptides prepared in PBS. (C) Effect of KCl buffer and PBS on the activity of 5 ng of PMT/ml. The x axis represents the volume of buffer added relative to the total volume of medium expressed as a percentage. (D) Competition results for 1-506/His in 100 mM imidazole buffer. The buffer controls were obtained by using equivalent volumes of imidazole buffer at each point instead of peptide. (E) Immunoprecipitation of PMT by different polyclonal antibodies. The antibodies used for immunoprecipitation were as follows: lanes 1 to 2, PBS buffer control; lanes 3 to 4, rabbit anti-PMT; lanes 5 to 6, preimmune sheep sera; lanes 7 to 8, anti-1-506; lanes 9 to 10, anti-1-506/His; lanes 11 to 12, anti-681-C; lanes 13 to 14, anti-849-C. Lanes 1, 3, 5, 7, 9, 11, and 13 contain supernatant; lanes 2, 4, 6, 8, 10, 12, and 14 contain protein eluted from beads.

Secondary structure analysis based on the primary amino acid sequence. The sequence identity between PMT and CNF1 was nearly 22% after sequence alignment with MALIGN (20). The presence of conserved and similar residues suggest a higher conservation in a region corresponding to residues 250 to 530 of the PMT sequence and is predicted to be significant by using the algorithm of Doolittle et al. (7). The alignment with CNF1 and the PHD results are consolidated in Fig. 7 to show the prominent features. These include four helix-rich regions at positions 110 to 220, 379 to 498, 590 to 720, and 820 to 875. Regions 225 to 285 and 515 to 590 are potentially beta rich, while regions 50 to 100, 285 to 350, and 889 to 1280 are alternating / folds. The assignment of these regions is supported by weak homology to proteins of known structure (Fig. 7). For example, the predicted helix-rich region between residues 593 and 720 is supported by marginal homology to the highly helical protein tropinin C (40).

View larger version (20K): [in this window] [in a new window]   FIG. 7.   Structural predictions of PMT. (A) The location of predicted , , and mixed / regions is shown based on the PHD analysis of the PMT amino acid sequence aligned with CNF. The predicted hydrophobic region was described by Lax et al. (27). The location of the eight cysteine (C) residues is shown. The narrow solid bars indicate the location and extent of regions of weak homology to proteins of known structure (see the text): the broader bar indicates homology to CNF. The arrow indicates the start (amino acid 917) of the analysis by the THREADER 2 program.

	DISCUSSION

Top Abstract Introduction Materials and Methods Results Discussion References

The work presented here demonstrates that the C terminus of PMT (residues 681 to 1285) possesses catalytic activity. Microinjection of this fragment led to the typical cell morphology associated with toxin treatment. More importantly, this peptide stimulated quiescent cells to undergo DNA synthesis, showing that it is mitogenic, the most striking and distinctive activity of this toxin.

The identification of the catalytic domain was supported by the inhibitory effect of antibodies to the C terminus after microinjection into the cytoplasm of Swiss 3T3 cells. We also showed that the inactive mutant C1165S (53) competes with native PMT for interaction with cells, and this provided further indirect evidence that this C-terminal point mutation affected enzymatic activity. The C terminus was predicted to be folded into an alternating / structure that is commonly found in the catalytic domain of proteins. Threading calculations to fit this region to known structures lend further support to this idea, since the highest scoring protein has an / structure. Interestingly, the PMT fragment GST/849-C was not catalytically active, although it contained the predicted / domain.

Our assignment of catalytic activity to the C terminus of PMT is supported by a very recent publication (2) that showed that a slightly larger C-terminal fragment (residues 581 to 1285) could induce cytoskeletal changes typical of PMT and induce inositol phosphate production after electroporation into embryonic bovine lung cells. In contrast, Wilson et al. (56) showed that microinjection of PMT into voltage clamped Xenopus oocytes activated the inositol triphosphate signaling pathway, leading to Ca²⁺-induced Cl currents, and that this response was also observed after microinjection of an N-terminal fragment (residues 1 to 568 [55]). However, the two-peak response obtained with whole toxin was not clearly observed with this fragment, and the response may have been an artifact due to the hydrophobic domain present in this fragment inserting into the membrane. Indeed, when deletions were made from residue 568 into the predicted hydrophobic helical region, the response was gradually lost, with residues 1 to 400 being completely inactive.

The C-terminal peptides are predicted to contain a hydrophobic region (27) and were found in the insoluble fraction when their expression was induced at 37°C but were soluble when expressed at 30°C. Storage in PBS led to these peptides apparently competing with toxin in binding competition assays, suggesting that they either bound to cells or aggregated with toxin molecules. This did not occur when the peptides were prepared in potassium chloride microinjection buffer. Interestingly, this buffer resembles the physiological environment of the cytoplasm, where the catalytic domain would function.

This is the first report showing that the N terminus of PMT (residues 1 to 506) binds to cells, effectively competing with full-length toxin. The inhibitory effect of placing a fusion tag on the N terminus of this fragment suggests that the binding site did not fold properly in this construct and may therefore be very close to the N terminus. This would be analogous to CNF, in which the N-terminal 190 amino acids are sufficient for binding (8). Antibodies to the N terminus of PMT bound strongly to full-length toxin, showing that this domain is surface located, as would be expected for a receptor-binding domain. The receptor for PMT has not yet been identified, although there is some evidence that it binds to a ganglioside-type receptor (35). We showed, by Schild plot analysis, that PMT has an apparent binding affinity for surface receptors on Swiss 3T3 cells of ca. 1.5 × 10⁹ M. This is comparable to the binding affinity of other toxins such as diphtheria toxin (DT) (19). Interestingly, the apparent binding affinity of CNF to Hep2 cells was higher by ca. 2 orders of magnitude (5) in spite of the homology between PMT and CNF, indicating diverse toxin-receptor interactions. The localization of the binding domain of PMT will facilitate the identification of the receptor and allow different types of cells to be analyzed for their ability to bind toxin.

The region of highest homology between PMT and the related toxin CNF corresponds to PMT residues 250 to 530 (which corresponds to CNF residues 200 to 465). This region in CNF is not essential for cell binding or catalytic activity and is assumed to contain the membrane translocation domain (28). This region of PMT, which was predicted to be hydrophobic and helical, is likely to have a similar role.

Limited digestion of toxins with proteases has frequently been used to separate functional domains; for example, DT is cleaved into its constituent A and B fragments by trypsin (12). PMT is highly resistant to proteolysis at neutral pH (46), but Asp-N did cleave the toxin in two positions (after residues 473 and 509) just downstream of the proposed translocation domain. Similarly, the Bordetella DNT, which shares homology with CNF, as well as a similar domain organization, was reported to be cleaved into two fragments by trypsin, an N-terminal fragment of 60 kDa and a C-terminal fragment of 90 kDa (22). It remains unknown whether PMT, DNT, or CNF is cleaved during the intoxication process. However, it is notable that PMT has a motif for cleavage by the mammalian protease furin (54) at residues 515 to 520 (KIRLVR), and this is a possible site for in vivo cleavage of PMT. Furin is involved in the cleavage and activation of several bacterial toxins, including protective antigen from Bacillus anthracis, Pseudomonas exotoxin A, and DT (13).

The development of assays for intracellular activity and binding and the localization of the functional domains of PMT will allow us to investigate its molecular mode of action in more detail.